IPSEN (OTCMKTS:IPSEY) Reaches New 1-Year High – What’s Next?

IPSEN (OTCMKTS:IPSEY) shares reached a new 52-week high on Tuesday . The company traded as high as $51.10 and last traded at $51.10, with a volume of 1519 shares traded. The stock had previously closed at $49.0850.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on IPSEY shares. UBS Group lowered shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold”.

IPSEN Stock Performance

The stock’s 50 day moving average is $46.75 and its 200-day moving average is $40.60.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).